The GRADE studies evaluated the pharmacotherapy of diabetes after initiation of metformin – for both micro- and macrovascular outcomes. Join host, Geoff Wall, and guest Jake Galdo as they examine these studies to determine if they are GameChangers in diabetes management.

The GameChanger
Insulin glargine and liraglutide had the biggest decrease in A1c; however, many patients still did not reach goal targets. Minor differences in microvascular and macrovascular outcomes were observed.

Show Segments
00:00 - Introductions

1:40 - The GRADE Studies

12:02 - Glycemic Outcomes

16:08 - Microvascular and Cardiovascular Outcomes

21:10 - The GameChanger: Selecting a Second Medication

27:18 - Connecting to Practice: Realistic Diabetes Care

33:17 - Closing Remarks

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Guest
John A Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Director, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad


References and Resources

• Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes
• Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular 

Redeem your CPE or CME here

• CPE (Pharmacist)
• CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)

• Pharmacists: Get a membership
• Prescribers: Get a membership

CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Select a second medication after metformin in a patient with type 2 diabetes based on the data from the GRADE studies
2. Discuss the results of the GRADE studies

0.05 CEU/0.5 Hr
UAN: 0107-0000-22-401-H01-P
Initial release date: 10/31/2022
Expiration date: 10/31/2023
Additional CPE and CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram